Blood test may predict success of liver surgery for rare eye cancer
NCT ID NCT02849145
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at whether measuring tumor DNA in the blood can help doctors know if surgery to remove liver metastases from uveal melanoma was successful. Researchers took blood samples from 60 patients before and after surgery and during follow-up. The goal was to see if changes in tumor DNA levels matched with complete removal of the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a blood test that helps doctors know if surgery completely removed liver metastases from uveal melanoma.
- What could go wrong
- This is a small, early-stage study focused on measuring a biomarker, not testing a treatment. The results may not change patient care or apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Curie
Paris, 75005, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking a rare eye cancer pave the way for new treatments?
- Can a new drug tame advanced solid tumors?
- Can a single eye injection shrink melanoma and save sight?
- Supercharged immune cells take aim at childhood cancers
- Can a pill prevent eye cancer spread? new trial aims to find out
- New drug shows promise in shrinking eye cancer before surgery